Impact of the Metabolic Syndrome on the Clinical Outcome of Patients with Acute ST-Elevation Myocardial Infarction

다국어 초록 (Multilingual Abstract)

We sought to determine the prevalence of metabolic syndrome (MS) in patients with acute myocardial infarction and its effect on clinical outcomes. Employing data from the Korea Acute Myocardial Infarction Registry, a total of 1,990 patients suffered from acute STelevation myocardial infarction (STEMI) between November 2005 and December 2006were categorized according to the National Cholesterol Education Program-Adult Treatment Panel III criteria of MS. Primary study outcomes included major adverse cardiac events (MACE) during one-year follow-up. Patients were grouped based on existence of MS: group I: MS (n=1,182, 777 men, 62.8±12.3 yr); group II: Non-MS (n=808, 675 men,64.2±13.1 yr). Group I showed lower left ventricular ejection fraction (LVEF) (P=0.005).
There were no differences between two groups in the coronary angiographic findings except for multivessel involvement (P=0.01). The incidence of in-hospital death was higher in group I than in group II (P=0.047), but the rates of composite MACE during one-year clinical follow-up showed no significant differences. Multivariate analysis showed that low LVEF, old age, MS, low high density lipoprotein cholesterol and multivessel involvement were associated with high in-hospital death rate. In conclusion, MS is an important predictor for in-hospital death in patients with STEMI.

참고문헌 (Reference)

1 차봉수, "대사 증후군에서 관동맥 질환 발생의 기전 및 예방과 치료" 대한심장학회 33 (33): 645-652, 2003

2 Lean ME, "Waist circumference as a measure for indicating need for weight management" 331 : 158-161, 1995

3 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report" 106 : 3143-3421, 2002

4 Olijhoek JK, "The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm" 25 : 342-348, 2004

5 Lakka HM, "The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men" 288 : 2709-2716, 2002

6 Girman CJ, "The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex- CAPS)" 93 : 136-141, 2004

7 Gale EA, "Should we dump the metabolic syndrome?" 336 : 640-, 2008

8 Sim DS, "Safety and benefit of early elective percutaneous coronary intervention after successful thrombolytic therapy for acute myocardial infarction" 103 : 1333-1338, 2009

9 Knowler WC, "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin" 346 : 393-403, 2002

10 Rantala AO, "Prevalence of the metabolic syndrome in drug-treated hypertension patients and control subjects" 245 : 163-174, 1999

11 Zeller M, "Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction" 165 : 1192-1198, 2005

12 Weiss R, "Obesity and the metabolic syndrome in children and adolescents" 350 : 2362-2374, 2004

13 Bartnik M, "Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction" 25 : 1990-1997, 2004

14 Kahn R, "Metabolic syndrome: is it a syndrome? Does it matter?" 115 : 1806-1811, 2007

15 Sattar N, "Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study" 108 : 414-419, 2003

16 Levantesi G, "Metabolic syndrome and risk of cardiovascular events after myocardial infarction" 46 : 277-283, 2006

17 Wannamethee SG, "Measures of adiposity in the identification of metabolic abnormalities in elderly men" 81 : 1313-1321, 2005

18 Yudkin JS, "Low grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study" 53 : 852-857, 2004

19 Ferrannini E, "Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome" 34 : 416-422, 1991

20 Lee KH, "Gender differences of success rate of percutaneous coronary intervention and short term cardiac events in Korea Acute Myocardial Infarction Registry" 130 : 227-234, 2008

21 Manginas A, "Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method" 83 : 1562-1565, 1999

22 Solymoss BC, "Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity" 93 : 159-164, 2004

23 Grundy SM, "Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement" 112 : 2735-2752, 2005

24 Kini AS, "Coronary angiography, lesion classification and severity assessment" 24 : 153-162, 2006

25 Grundy SM, "Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management" 109 : 551-556, 2004

26 Kip KE, "Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) Study" 109 : 706-713, 2004

27 French JK, "Clinical implications of the new definition of myocardial infarction" 90 : 99-106, 2004

28 Isomaa B, "Cardiovascular morbidity and mortality associated with the metabolic syndrome" 24 : 683-689, 2001